Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase 1, First-in-human, Single-center, Safety, Tolerability, Ventricular Repolarization and Pharmacokinetic Study of Single and Multiple Ascending Doses of KAR5585 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rodatristat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; First in man
- Sponsors Karos Pharmaceuticals
- 22 Oct 2019 According to an Altavant Sciences media release, data from this trial was presented at the American College of Chest Physicians CHEST Annual Meeting 2019 in New Orleans.
- 22 Oct 2019 Results presented in an Altavant Sciences media release.
- 18 Oct 2019 According to an Altavant Sciences media release, data from this study will be presented at the American College of Chest Physician's annual CHEST 2019 meeting.